UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
____________
FORM 8‑K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): February 18, 2014
|
|
| The Medicines Company |
| (Exact Name of Registrant as Specified in Charter) |
|
| | | | |
| Delaware | | 000-31191 | | 04-3324394 |
(State or Other Jurisdiction of Incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
|
| | |
8 Sylvan Way Parsippany, New Jersey | | 07054 |
| (Address of Principal Executive Offices) | | (Zip Code) |
Registrant's telephone number, including area code: (973) 290-6000
|
|
| |
| (Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| |
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective March 3, 2014, Paul M. Antinori will transition from his role as General Counsel and Secretary of The Medicines Company (the "Company") to thereafter create and lead the Company’s global government affairs function and continue to assist on significant transactions and other matters. Subsequent to Mr. Antinori's role change, he will no longer be a Section 16 officer or executive officer of the Company. Stephen M. Rodin, currently Vice President, Deputy General Counsel for the Company, will assume the role of Senior Vice President, General Counsel and Secretary as of March 3, 2014.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
THE MEDICINES COMPANY
| |
| Date: February 24, 2014 | By: /s/ Paul M. Antinori |
Paul M. Antinori
Senior Vice President and General Counsel
